ReviewInternational journal of nanomedicine2020
Nanoparticle Drug Delivery System for Glioma and Its Efficacy Improvement Strategies: A Comprehensive Review.
Review in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 176 citations in OpenAlex.
- A Systematic Review of Nanoparticle-Mediated Ferroptosis in Glioma Therapy.International journal of nanomedicine · 2025Pooled it
- Personalised therapeutic approaches to glioblastoma: A systematic review.Frontiers in medicine · 2023Pooled it
- Ferroptosis as an immunometabolic checkpoint in brain tumours: spatial vulnerabilities and therapeutic opportunities.Molecular brain · 2026Review
- A flexibility-driven delivery strategy for cationic liposomes to enhance tumor penetration and promote membrane fusion-mediated cellular entry.Materials today. Bio · 2026Article
- Multiscale analysis and optimal glioma therapeutic candidate discovery using the CANDO platform.Journal of cheminformatics · 2026Article
- Peptide Drugs in Gastrointestinal Tumors: Integrating Targeting, Delivery, and Therapeutic Actions for Synergistic Strategies.Biomolecules · 2026Review
- Peptide-Based Nanocarriers for Targeted Drug Delivery: Recent Advances, Strategies, and Therapeutic Frontiers.International journal of nanomedicine · 2026Review
- Pathophysiological and Etiological Corroborations for the Mechanistic Design of Intranasal Therapies in Glioblastoma Multiforme.Current pharmaceutical design · 2026Review
- Engineered Extracellular Vesicles in Glioma Therapy: Recent Advances and Applications.International journal of nanomedicine · 2026Review
- Combination Cancer Therapy and Reference Models for Assessing Drug Synergy in Glioblastoma.Current oncology (Toronto, Ont.) · 2025Review
- Advancing glioblastoma therapy with surface-modified nanoparticles.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Review
- Research Strategies and Methods of Hydrogels for Antitumor Drug Delivery.Biomedicines · 2025Review
- Peptide Drug: Design and Clinical Applications.MedComm · 2025Review
- Development of modern Chinese medicine guided by molecular compatibility theory.Journal of advanced research · 2025Review
- Taurochenodeoxycholic acid suppresses the progression of glioblastoma via HMGCS1/HMGCR/GPX4 signaling pathway in vitro and in vivo.Cancer cell international · 2025Article
- Innovations in Cancer Therapy: Endogenous Stimuli-Responsive Liposomes as Advanced Nanocarriers.Pharmaceutics · 2025Review
- Nootkatone inhibits the progression of glioblastoma by activating the ATF4-CHOP-CHAC1 pathway.Molecular medicine (Cambridge, Mass.) · 2025Article
- Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.Biomimetics (Basel, Switzerland) · 2025Review
- A comprehensive insight of innovations and recent advancements in nanocarriers for nose-to-brain drug targeting.Designed monomers and polymers · 2025Review
- Self-Assembled Nanoplatform with pH/NIR Light-Responsive Drug Delivery for Combined Therapy of Glioma in vitro.International journal of nanomedicine · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gliomas are the most common tumor of the central nervous system. However, the presence of the brain barrier blocks the effective delivery of drugs and leads to the treatment failure of various drugs. The development of a nanoparticle drug delivery system (NDDS) can solve this problem. In this review, we summarized the brain barrier (including blood-brain barrier (BBB), blood-brain tumor barriers (BBTB), brain-cerebrospinal fluid barrier (BCB), and nose-to-brain barrier), NDDS of glioma (such as passive targeting systems, active targeting systems, and environmental responsive targeting systems), and NDDS efficacy improvement strategies and deficiencies. The research prospect of drug-targeted delivery systems for glioma is also discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.